KYORIN Pharmaceutical Co., Ltd. (TYO:4569)
Japan
· Delayed Price · Currency is JPY 1,592.00
-4.00 (-0.25%)
Mar 14, 2025, 3:30 PM JST
KYORIN Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Revenue | 121,551 | 119,532 | 113,270 | 105,534 | 102,904 | 109,983 | Upgrade
|
| Revenue Growth (YoY) | 1.44% | 5.53% | 7.33% | 2.56% | -6.44% | -3.20% | Upgrade
|
| Cost of Revenue | 69,785 | 68,124 | 63,102 | 56,093 | 51,276 | 52,950 | Upgrade
|
| Gross Profit | 51,766 | 51,408 | 50,168 | 49,441 | 51,628 | 57,033 | Upgrade
|
| Selling, General & Admin | 39,083 | 37,375 | 34,140 | 35,536 | 36,138 | 38,541 | Upgrade
|
| Research & Development | 8,019 | 8,019 | 10,903 | 8,897 | 9,703 | 10,987 | Upgrade
|
| Operating Expenses | 47,121 | 45,402 | 45,047 | 44,437 | 45,853 | 49,543 | Upgrade
|
| Operating Income | 4,645 | 6,006 | 5,121 | 5,004 | 5,775 | 7,490 | Upgrade
|
| Interest Expense | -120 | -66 | -66 | -66 | -68 | -75 | Upgrade
|
| Interest & Investment Income | 502 | 500 | 465 | 410 | 420 | 427 | Upgrade
|
| Earnings From Equity Investments | 29 | -12 | - | 25 | 49 | 19 | Upgrade
|
| Currency Exchange Gain (Loss) | 85 | 59 | 78 | 98 | 129 | 106 | Upgrade
|
| Other Non Operating Income (Expenses) | 160 | 114 | 228 | 97 | 143 | 208 | Upgrade
|
| EBT Excluding Unusual Items | 5,301 | 6,601 | 5,826 | 5,568 | 6,448 | 8,175 | Upgrade
|
| Gain (Loss) on Sale of Investments | 411 | 1,403 | 70 | -320 | 488 | 104 | Upgrade
|
| Gain (Loss) on Sale of Assets | -131 | -90 | -15 | -32 | 342 | -24 | Upgrade
|
| Asset Writedown | - | - | -257 | - | - | - | Upgrade
|
| Other Unusual Items | -143 | -896 | 1,281 | - | 1,074 | - | Upgrade
|
| Pretax Income | 5,438 | 7,018 | 6,905 | 5,216 | 8,352 | 8,255 | Upgrade
|
| Income Tax Expense | 1,591 | 1,696 | 2,182 | 1,284 | 2,222 | 2,106 | Upgrade
|
| Net Income | 3,847 | 5,322 | 4,723 | 3,932 | 6,130 | 6,149 | Upgrade
|
| Net Income to Common | 3,847 | 5,322 | 4,723 | 3,932 | 6,130 | 6,149 | Upgrade
|
| Net Income Growth | -9.69% | 12.68% | 20.12% | -35.86% | -0.31% | -10.48% | Upgrade
|
| Shares Outstanding (Basic) | 57 | 57 | 57 | 57 | 57 | 57 | Upgrade
|
| Shares Outstanding (Diluted) | 57 | 57 | 57 | 57 | 57 | 57 | Upgrade
|
| Shares Change (YoY) | 0.17% | 0.15% | 0.00% | 0.01% | 0.02% | -12.70% | Upgrade
|
| EPS (Basic) | 66.96 | 92.73 | 82.42 | 68.62 | 106.99 | 107.34 | Upgrade
|
| EPS (Diluted) | 66.96 | 92.73 | 82.42 | 68.62 | 106.99 | 107.34 | Upgrade
|
| EPS Growth | -9.85% | 12.51% | 20.11% | -35.86% | -0.33% | 2.54% | Upgrade
|
| Free Cash Flow | - | -4,229 | -4,322 | 3,902 | 1,122 | 5,115 | Upgrade
|
| Free Cash Flow Per Share | - | -73.69 | -75.42 | 68.10 | 19.58 | 89.29 | Upgrade
|
| Dividend Per Share | 52.000 | 52.000 | 52.000 | 52.000 | 75.000 | 75.000 | Upgrade
|
| Dividend Growth | -27.78% | 0% | 0% | -30.67% | 0% | 0% | Upgrade
|
| Gross Margin | 42.59% | 43.01% | 44.29% | 46.85% | 50.17% | 51.86% | Upgrade
|
| Operating Margin | 3.82% | 5.02% | 4.52% | 4.74% | 5.61% | 6.81% | Upgrade
|
| Profit Margin | 3.16% | 4.45% | 4.17% | 3.73% | 5.96% | 5.59% | Upgrade
|
| Free Cash Flow Margin | - | -3.54% | -3.82% | 3.70% | 1.09% | 4.65% | Upgrade
|
| EBITDA | 9,273 | 10,296 | 8,961 | 8,718 | 9,339 | 10,711 | Upgrade
|
| EBITDA Margin | 7.63% | 8.61% | 7.91% | 8.26% | 9.08% | 9.74% | Upgrade
|
| D&A For EBITDA | 4,628 | 4,290 | 3,840 | 3,714 | 3,564 | 3,221 | Upgrade
|
| EBIT | 4,645 | 6,006 | 5,121 | 5,004 | 5,775 | 7,490 | Upgrade
|
| EBIT Margin | 3.82% | 5.02% | 4.52% | 4.74% | 5.61% | 6.81% | Upgrade
|
| Effective Tax Rate | 29.26% | 24.17% | 31.60% | 24.62% | 26.60% | 25.51% | Upgrade
|
| Advertising Expenses | - | 5,593 | 4,714 | 4,731 | 5,784 | 7,148 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.